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Abstract 
Background: Blood eosinophil count (BEC) and fractional exhaled nitric oxide (FeNO) concentration are established 
biomarkers in asthma, associated particularly with the risk of exacerbations. We evaluated the relationship of BEC and 
FeNO as complementary and independent biomarkers of severe asthma exacerbations.
Methods: This observational study included data from the Optimum Patient Care Research Database. Asthma 
patients (18–80 years) with valid continuous data for 1 year before FeNO reading, ≥ 1 inhaled corticosteroid prescrip‑
tion, and BEC recorded ≤ 5 years before FeNO reading were separated into cohorts. Categorisation 1 was based on 
the American Thoracic Society criteria for elevated FeNO concentration (high: ≥ 50 ppb; non‑high: < 25 ppb) and BEC 
(high: ≥ 0.300 × 109 cells/L; non‑high: < 0.300 × 109 cells/L). Categorisation 2 (FeNO concentration, high: ≥ 35 ppb; 
non‑high: < 35 ppb) was based on prior research. Reference groups included patients with neither biomarker raised.
Results: In categorisation 1, patients with either high FeNO or high BEC (n = 200) had a numerically greater exacer‑
bation rate (unadjusted rate ratio, 1.31 [95% confidence interval: 0.97, 1.76]) compared with patients in the reference 
group. Combination of high FeNO and high BEC (n = 27) resulted in a significantly greater exacerbation rate (3.67 
[1.49, 9.04]). Similarly, for categorisation 2, when both biomarkers were raised (n = 53), a significantly greater exacerba‑
tion rate was observed (1.72 [1.00, 2.93]).
Conclusion: The combination of high FeNO and high BEC was associated with significantly increased severe exacer‑
bation rates in the year preceding FeNO reading, suggesting that combining FeNO and BEC measurements in primary 
care may identify asthma patients at risk of exacerbations.
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Background
Asthma, a chronic inflammatory disorder of the airways 
affecting more than 315 million people worldwide, is 
associated with considerable morbidity, mortality, and 
loss of productivity [1–3]. Recognised as a complex, 
heterogeneous disease, asthma is associated with sev-
eral phenotypes [4]. Approximately 50% of all asthma 
patients demonstrate evidence of eosinophilic airway 
inflammation [5, 6], which is associated with an increased 
risk of exacerbations [7, 8]. Severe asthma exacerbations 
involve systemic corticosteroid use, emergency room vis-
its, and/or hospitalisations [9, 10]. Therefore, an impor-
tant goal in the treatment and management of asthma is 
preventing exacerbations by identifying patients most at 
risk.
Blood eosinophil counts and fractional exhaled nitric 
oxide (FeNO) concentrations are established biomark-
ers in asthma. A high blood eosinophil count, used as 
a marker for eosinophilic airway inflammation, corre-
lates well with poor asthma control, an increased risk of 
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Conversely, a significant reduction in severe exacerba-
tions has been observed for severe asthma patients with 
elevated blood eosinophils treated with biologics tar-
geting type 2 cytokines involved in eosinophilic inflam-
mation [15–18]. A FeNO concentration greater than 50 
parts per billion (ppb) is a marker for eosinophilic airway 
inflammation and predicts the likelihood of corticoster-
oid responsiveness [19, 20]. Moreover, elevated FeNO is 
considered a risk factor for exacerbations in adult asthma 
patients prescribed inhaled corticosteroids (ICS) [21, 22]. 
Therefore, measurement of FeNO may provide additional 
predictive value to blood eosinophil counts for severe 
exacerbations in asthma patients.
Although both blood eosinophil count and FeNO 
concentration are associated with eosinophilic airway 
inflammation, they demonstrate only a modest correla-
tion, reflecting different parts of the T2-driven inflam-
mation [23–26]. Notably, these biomarkers vary in their 
responsiveness to and ability to predict response to bio-
logic therapy for asthma [16, 27, 28].
Anti-interleukin-5 treatment with mepolizumab low-
ered blood eosinophil counts without affecting FeNO 
concentrations [28], while blocking interleukin-13 with 
lebrikizumab reduced FeNO concentrations without 
affecting blood eosinophil counts [27]. Thus, FeNO 
may also reflect aspects of T2-driven inflammation not 
directly related to eosinophils. While strong evidence 
suggests that ICS treatment has a substantial effect on 
FeNO readings, sparse evidence supports the dose–
response effect of ICS on blood eosinophil counts [24, 
25]. Presence of raised FeNO concentrations and raised 
blood eosinophil counts, despite adherence to treatment, 
may identify patients with poor sensitivity to ICS who 
require a more targeted, personalised approach to ther-
apy. Therefore, identification of a phenotype that dem-
onstrates raised blood eosinophil counts and/or FeNO 
concentrations, despite ICS therapy, could be valuable. 
The aim of this study was to determine whether FeNO 
concentration added value to blood eosinophil counts 
for identification of patients at risk of asthma exacerba-
tions. We, therefore, retrospectively analysed data from a 
large validated national database of patients in the United 
Kingdom (UK) to evaluate whether a high blood eosin-
ophil count combined with high FeNO concentration 
was associated with an increased risk of severe asthma 
exacerbations.
Methods
Data source and study design
This cross-sectional study was conducted using patient 
data from the Optimum Patient Care Research Data-
base (OPCRD). The OPCRD  is a primary care database 
containing high-quality anonymised data obtained from 
longitudinal medical records and patient-completed 
questionnaires in the UK health care system [29]. Patient 
data were assessed for 1  year preceding the index date 
(baseline year). The study was registered under the estab-
lished study database, namely, the European Network 
of Centres for Pharmacoepidemiology and Pharma-
covigilance (registration number: EUPAS16891). Ethical 
approvals were obtained from the Anonymised Data Eth-
ics and Protocol Transparency committee [30].
Patients were classified based on their FeNO reading 
on the index date and the closest blood eosinophil count 
reading (Fig.  1). Two sets of thresholds were used for 
FeNO: (1) based on the American Thoracic Society (ATS) 
[19] criteria defining high FeNO (≥ 50  ppb), medium 
FeNO (25 to < 50  ppb), and low FeNO (< 25  ppb) con-
centrations (categorisation 1); and (2) based on previous 
research [31, 32] suggesting poor asthma control with 
FeNO concentrations ≥ 35  ppb, high FeNO was defined 
as ≥ 35 ppb and non-high FeNO, < 35 ppb (categorisation 
2). In both categorisation schemes, the cutoff to define 
a high blood eosinophil count was set at ≥ 0.300 × 109 
cells/L. Categorisation 1 included three cohorts: high 
FeNO (≥ 50  ppb) and high blood eosinophil count 
(≥ 0.300 × 109 cells/L), high FeNO alone (≥ 50  ppb) 
or high blood eosinophil count alone (≥ 0.300 × 109 
cells/L), and non-high FeNO (< 25  ppb) and non-high 
blood eosinophil count (< 0.300 × 109 cells/L) (refer-
ence group). Categorisation 2 included four cohorts: 
high FeNO (≥ 35 ppb) and high blood eosinophil count 
(≥ 0.300 × 109 cells/L), high FeNO (≥ 35  ppb) and non-
high blood eosinophil count (< 0.300 × 109 cells/L), non–
high FeNO (< 35  ppb) and high blood eosinophil count 
(≥ 0.300 × 109 cells/L), and non-high FeNO (< 35  ppb) 
and non-high blood eosinophil count (< 0.300 × 109 
cells/L) (reference group).
The study period, during which both patient character-
istics and outcomes were observed, consisted of the year 
prior to the latest documented FeNO reading.
Patients
The study population consisted of patients who met the 
following criteria: age 18–80  years inclusive; a diagnos-
tic Read code for asthma qualifying for inclusion in the 
asthma patient registry, which general practices in the 
UK maintain for the Quality Outcomes Framework [33]; 
active asthma with ≥ 1 prescription for asthma medica-
tion, including ICS in the year prior to the index date; ≥ 1 
valid blood eosinophil count recorded without a recent 
exacerbation (within 2  weeks) at most ≤ 5  years before 
FeNO reading; and valid continuous data for 1 year prior 
to the latest FeNO reading.
Patients were excluded from the study if they had a 
diagnosis Read code for chronic obstructive pulmonary 
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disease or any chronic respiratory disease other than 
asthma; received a long-acting muscarinic antagonist or 
were prescribed maintenance oral corticosteroids (OCS); 
and had a forced expiratory volume in 1  s/forced vital 
capacity < 0.7.
Outcomes
The primary outcome was the annual rate of severe 
asthma exacerbations, defined as the number of severe 
exacerbations in the study period per patient. A severe 
exacerbation was defined in line with the European 
Respiratory Society/ATS Position Statement [9] as an 
acute prescription of OCS, or an unplanned lower res-
piratory tract-related hospitalisation, or an accident and 
emergency attendance associated with a lower respira-
tory Read code or primary care respiratory consultation 
within 14 days.
Secondary outcomes included a description of demo-
graphics, lung function, comorbidities, respiratory medi-
cation use and ICS adherence for each of the patient 
groups characterised by biomarker concentrations. ICS 
adherence was defined using Medication Possession 
Ratio, calculated by dividing the total of 1 day’s supply by 
the total number of days evaluated (365 days in the study 
year), and expressed in percentage.
Statistical analyses
All statistical analyses were conducted using Stata SE ver-
sion 14.2 and R version 3.0.2.
The sample size was calculated by accounting for multi-
ple testing with a Bonferroni correction. With four com-
parisons and an alpha significance level of 0.0125, 800 
patients were initially deemed necessary to demonstrate 
at least a 20% difference between groups, with a 90% 
power. However, this was later revised to detect a differ-
ence in a single outcome only, namely, a 20% difference in 
exacerbation rate between two groups of interest.
Comparisons were initially unmatched for the purpose 
of exploring the main differences between patient groups 
and providing the steering committee with data in order 
to make a decision on which patient groups to compare. 
In addition, multivariate regression models were fitted to 
Fig. 1 Study design. The study period consisted of the year prior to the latest documented FeNO reading. FeNO fractional exhaled nitric oxide
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account for potential confounding of patient characteris-
tics that may have varied between patient groups. Stand-
ardised mean difference was calculated to measure effect 
size. Characterisation and subsequent matched analyses 
of study outcomes were performed based on categorisa-
tions 1 and 2. Descriptive statistics of all characteristics 
were computed for each group of patients within the 
cohorts. Continuous variables were summarised using 
the number and percentage of non-missing observa-
tions, mean and standard deviation (SD) for normally 
distributed variables, and median and interquartile range 
(difference between the 25th and 75th percentiles) for 
non-normally distributed variables. Pearson’s Chi square 
test was used to compare percentages between different 
groups, with a Fisher’s test used in cases of small num-
bers of observations per group. Student’s t test was used 
to compare a continuous variable between two groups, 
with a non-parametric Mann–Whitney test used for 
small numbers of observations per group. Summary sta-
tistics were presented as counts and percentages. For 
missing data, percentages for categorical variables were 
provided as a percentage of the non-missing observa-
tions. A statistically significant result was defined as a 
p ≤ 0.05.
The primary analysis for categorisation 1 compared 
the number of severe exacerbations for matched patients 
with a high FeNO and high blood eosinophil count 
with that of patients with a non-high FeNO and non-
high blood eosinophil count (reference group). The rate 
of severe exacerbations was also compared between 
matched patients with a high FeNO or a high blood 
eosinophil count vs. the reference group. The analysis 
for categorisation 2 compared patients with a high FeNO 
and high blood eosinophil count vs. the reference group, 
a high blood eosinophil count alone vs. the reference 
group, and a high FeNO alone vs. the reference group.
Conditional Poisson regression analysis was performed 
to estimate the rate ratio (RR) between the groups of 
interest, with a 95% confidence interval (CI). Unadjusted 
RRs were calculated based on previous knowledge of 
multivariable prediction models [34, 35].
Results
At the time of the study, the OPCRD contained more 
than 2.4 million available patient records from more 
than 560 practices across the UK (Fig.  2). According to 
the records, 1268 patients had a recorded FeNO reading 
and of these, 610 patients met all other eligibility criteria 
and were included in the study population. Unmatched 
comparisons were made to assist with determining the 
eventual matching criteria. An additional file shows 
that differences were observed in sex, smoking status, 
body mass index (BMI), and prescription of OCS in the 
study year (Additional file 1: Tables S1, S2). Patients were 
matched 1:1 on age (within 10 years), sex, and smoking 
status. Further criteria to match were not included to 
preserve numbers in the cohort of interest.
Patients were subsequently categorised based on 
FeNO concentration and blood eosinophil count, such 
that patients from each subgroup with at least one ele-
vated variable of interest (FeNO and/or blood eosinophil 
count) were matched 1:1 with the reference group (non-
high FeNO and non-high blood eosinophil count).
Demographics and baseline clinical characteristics
Categorisation 1
A total of 27 patients in the high FeNO and high blood 
eosinophil cohort matched with the reference group 
(Table  1). Overall, 63% of patients were female, with 
most patients aged 35–65  years. In addition, 51.9% 
of patients were non-smokers. In the second cohort, 
200 patients with high FeNO or high blood eosino-
phil count matched with the reference group (Table  2). 
Overall, 58% of patients were female, with most patients 
aged 35–65  years. A total of 36.5% of patients were 
non-smokers.
Demographics and clinical characteristics were gener-
ally similar between the matched groups. However, stan-
dalone ICS prescriptions were significantly fewer in the 
high FeNO or high blood eosinophil cohort compared 
with the reference group (0.6 vs. 1.4 mean standalone 
ICS prescriptions/patient, p = 0.0112). Adherence to ICS 
was comparable between matched groups and was 52.3% 
and 63.3% in the high FeNO and high blood eosinophil 
cohort and high FeNO or high blood eosinophil cohort, 
respectively.
Categorisation 2
Across the biomarker cohorts, more than 50% of patients 
were female, with most patients aged 35–65 years. Non-
smokers represented 36–58.5% of the study sample.
Patients in the non-high FeNO and high blood eosino-
phil cohort, high FeNO and non-high blood eosinophil 
cohort, and high FeNO and high blood eosinophil cohort 
had significantly lower BMI compared with the reference 
group (29.0 vs. 30.1  kg/m2, p = 0.0492; 26.9 vs. 29.3  kg/
m2, p = 0.0063; and 26.8 vs. 29.0  kg/m2, p = 0.0386, 
respectively). All other baseline demographics were 
well-balanced between the matched groups (Tables 3, 4, 
5). For comorbidities, a greater number of patients had 
a diagnosis of rhinitis in the non-high FeNO and high 
blood eosinophil cohort compared with the reference 
group (88 vs. 67 patients, p = 0.0272). In addition, differ-
ences were observed in the number of ICS prescriptions 
per patient. Patients in the non-high FeNO and high 
blood eosinophil cohort, as well as the high FeNO and 
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non-high blood eosinophil cohort, had fewer standalone 
ICS prescriptions per patient relative to the reference 
group (0.7 vs. 1.3 mean standalone ICS prescriptions/
patient, p = 0.0362 and 0.9 vs. 1.6, p = 0.0295, respec-
tively). Adherence to ICS was not significantly differ-
ent between matched groups and was 66.2%, 65.7%, and 
68.6% in the non-high FeNO and high blood eosinophil, 
high FeNO and non-high blood eosinophil, and high 
FeNO and high blood eosinophil cohorts, respectively.
Asthma Exacerbations
Categorisation 1
In the high FeNO and high blood eosinophil count 
cohort, a significantly greater percentage of patients were 
in the greater exacerbation categories compared with 
patients in the reference group (p = 0.0427) (Additional 
file  1: Table  S3). The mean (SD) number of exacerba-
tions was also significantly greater relative to the refer-
ence group (0.8 [1.0] vs. 0.2 [0.4]; p = 0.0109). Overall, the 
estimated rate of exacerbations in the high FeNO and 
high blood eosinophil cohort was statistically signifi-
cantly greater (unadjusted RR: 3.67 [95% CI: 1.49, 9.04], 
p = 0.005) compared with matched patients in the refer-
ence group (Fig. 3). Likewise, significantly more patients 
were in the greater exacerbation categories in the high 
FeNO or high blood eosinophil cohort compared with 
patients in the reference group (p = 0.0481); however, the 
mean (SD) number of exacerbations was not significantly 
different from that in the reference group (0.5 [0.8] vs. 
0.4 [0.6]; p = 0.3423) (Additional file  1: Table  S3). Over-
all, the exacerbation rate was numerically greater but did 
not reach statistical significance when compared with 
matched patients in the reference group (1.31 [95% CI: 
0.97, 1.76], p = 0.081).
Categorisation 2
In both the non-high FeNO and high blood eosino-
phil cohort and the high FeNO and non-high blood 
Fig. 2 Patient selection from OPCRD. COPD chronic obstructive pulmonary disease, FeNO fractional exhaled nitric oxide, ICS inhaled corticosteroid, 
OCS oral corticosteroid, OPCRD Optimum Patient Care Research Database
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Table 1 Categorisation 1: non-high FeNO and non-high blood eosinophils vs. high FeNO and high blood eosinophils
Characteristics Non-high FeNO and non-high blood 
eosinophils (n = 27)
High FeNO and high blood  
eosinophils (n = 27)
p-value
Sex
 n (% non‑missing) 27 (100.0) 27 (100.0) 1.0000
 Male 10 (37.0) 10 (37.0)
Age
 n (% non‑missing) 27 (100.0) 27 (100.0) 0.9379
 Mean (SD) 43.5 (18.8) 43.3 (19.0)
 Median (IQR) 41.0 (37.0) 41.0 (37.0)
Age group
 n (% non‑missing) 27 (100.0) 27 (100.0) 1.0000
 Under 35 12 (44.4) 12 (44.4)
 35–65 9 (33.3) 9 (33.3)
 66–80 6 (22.2) 6 (22.2)
Smoking status
 n (% non‑missing) 27 (100.0) 27 (100.0) 0.7645
 Non‑smoker 13 (48.1) 14 (51.9)
 Ex‑smoker 1 (3.7) 2 (7.4)
 Current smoker 13 (48.1) 11 (40.7)
BMI
 n (% non‑missing) 23 (85.2) 26 (96.3) 0.4346
 Mean (SD) 27.7 (7.2) 26.9 (6.4)
 Median (IQR) 26.8 (5.5) 25.5 (8.4)
Active eczema  diagnosisa
 n (% non‑missing) 27 (100.0) 27 (100.0) 0.6387
 Yes 3 (11.1) 2 (7.4)
Active rhinitis  diagnosisa
 n (% non‑missing) 27 (100.0) 27 (100.0) 0.2482
 Yes 7 (25.9) 11 (40.7)
Eczema diagnosis
 n (% non‑missing) 27 (100.0) 27 (100.0) 0.7801
 Yes 10 (37.0) 11 (40.7)
Rhinitis diagnosis
 n (% non‑missing) 27 (100.0) 27 (100.0) 0.1628
 Yes 8 (29.6) 13 (48.1)
IHD diagnosis
 n (% non‑missing) 27 (100.0) 27 (100.0) 0.5525
 Yes 2 (7.4) 1 (3.7)
Heart failure diagnosis
 n (% non‑missing) 27 (100.0) 27 (100.0)
 Yes 0 (0.0) 0 (0.0)
Hypertension diagnosis
 n (% non‑missing) 27 (100.0) 27 (100.0) 0.4436
 Yes 5 (18.5) 3 (11.1)
Diabetes diagnosis
 n (% non‑missing) 27 (100.0) 27 (100.0)
 Yes 0 (0.0) 0 (0.0)
GERD active diagnosis
 n (% non‑missing) 27 (100.0) 27 (100.0) 0.3128
 Yes 1 (3.7) 0 (0.0)
Page 7 of 18Price et al. Clin Transl Allergy            (2019) 9:41 
eosinophil cohort, the mean number of exacerbations 
was not significantly different from those for the ref-
erence groups (0.5 [0.9] vs. 0.4 [0.7], p = 0.3134 and 
0.5 [0.7] vs. 0.3 [0.6], p = 0.1332, respectively) (Addi-
tional file  1: Table  S3). While both groups demon-
strated a clear trend towards greater exacerbation 
rates (1.41 [95% CI: 0.91, 2.19], p = 0.124 and 1.35 [95% 
CI: 0.99, 1.84], p = 0.054, respectively) in comparison 
with the reference group, this did not reach statisti-
cal significance (Fig.  3). For the high FeNO and high 
blood eosinophil cohort (both biomarkers elevated), 
although the mean number of exacerbations was not 
significantly different from that in the reference group 
(0.7 [0.9] vs. 0.4 [0.7], p = 0.116) (Additional file  1: 
Table S3), a significantly greater exacerbation rate was 
observed (1.72 [95% CI: 1.00, 2.93], p = 0.050) com-
pared with the reference group (Fig. 3).
Discussion
With the development of new biologics that target eosin-
ophilic airway inflammation, accurate and easy-to-use 
biomarkers to predict asthma exacerbations and likely 
patient responses to treatment are needed. We con-
ducted a real-world matched cohort study to investigate 
the relationship between blood eosinophil count, FeNO 
readings, and the severe exacerbation rate observed in 
asthma patients prescribed ICS.
We observed that for categorisation 1, based on 
ATS criteria for FeNO cutoffs, patients with a high 
FeNO (≥ 50  ppb) and high blood eosinophil count 
(≥ 0.300 × 109 cells/L) were almost four-times as likely to 
have had a severe exacerbation compared with patients 
with non-high FeNO (< 25  ppb) and non-high blood 
eosinophil count (< 0.300 × 109 cells/L) in the year pre-
ceding the FeNO reading. In patients with either a high 
All values in the table are n (%) unless otherwise specified. High FeNO defined as ≥ 50 ppb; non-high FeNO < 25 ppb; high blood eosinophil count defined 
as ≥ 0.300 × 109 cells/L; non-high blood eosinophil count < 0.300 × 109 cells/L
ATS American Thoracic Society, BMI body mass index, FeNO fractional exhaled nitric oxide, GERD gastroesophageal reflux disease, ICS inhaled corticosteroid, IHD 
ischaemic heart disease, IQR interquartile range, LABA long-acting β2-agonist, ppb parts per billion, SABA short-acting β2-agonist, SD standard deviation
a Active denotes diagnosed in the year before FeNO reading or treated in the year before FeNO reading
b Medication Possession Ratio was calculated by dividing the total of 1 day’s supply by the total number of days evaluated, multiplied by 100%. The evaluation period 
for all patients was 365 days in the study year
Table 1 (continued)
Characteristics Non-high FeNO and non-high blood 
eosinophils (n = 27)
High FeNO and high blood  
eosinophils (n = 27)
p-value
Predicted peak flow
 n (% non‑missing) 14 (51.9) 20 (74.1) 0.9721
 Mean (SD) 488.9 (53.4) 505.8 (74.9)
 Median (IQR) 482.7 (47.2) 478.3 (127.7)
ICS/LABA prescriptions per patient
 n (% non‑missing) 27 (100.0) 27 (100.0) 0.6546
 Mean (SD) 3.6 (4.3) 3.2 (2.5)
 Median (IQR) 1.0 (7.0) 3.0 (5.0)
Mono ICS prescriptions per patient
 n (% non‑missing) 27 (100.0) 27 (100.0) 0.4898
 Mean (SD) 1.2 (1.9) 1.0 (2.2)
 Median (IQR) 0.0 (2.0) 0.0 (1.0)
Mean daily SABA dosage (µg)
 n (% non‑missing) 27 (100.0) 27 (100.0) 0.5066
 < 100 8 (29.6) 6 (22.2)
 100–200 11 (40.7) 8 (29.6)
 201–400 6 (22.2) 8 (29.6)
 > 400 2 (7.4) 5 (18.5)
ICS  adherenceb
 n (% non‑missing) 27 (100.0) 27 (100.0) 0.7158
 Mean (SD) 57.1 (39.3) 52.3 (32.9)
 Median (IQR) 54.8 (54.8) 49.3 (35.7)
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Table 2 Categorisation 1: non-high FeNO and non-high blood eosinophils vs. high FeNO or high blood eosinophils
Characteristics Non-high FeNO and non-high blood 
eosinophils (n = 200)




 n (% non‑missing) 200 (100.0) 200 (100.0) 1.0000
 Male 84 (42.0) 84 (42.0)
Age
 n (% non‑missing) 200 (100.0) 200 (100.0) 0.9223
 Mean (SD) 51.7 (13.1) 51.6 (13.2)
 Median (IQR) 54.0 (18.5) 53.0 (19.5)
Age group
 n (% non‑missing) 200 (100.0) 200 (100.0) 0.4289
 Under 35 24 (12.0) 25 (12.5)
 35–65 150 (75.0) 140 (70.0)
 66–80 26 (13.0) 35 (17.5)
Smoking status
 n (% non‑missing) 200 (100.0) 200 (100.0) 1.0000
 Non‑smoker 73 (36.5) 73 (36.5)
 Ex‑smoker 23 (11.5) 23 (11.5)
 Current smoker 71 (35.5) 71 (35.5)
BMI
 n (% non‑missing) 189 (94.5) 191 (95.5) 0.1025
 Mean (SD) 30.0 (6.9) 29.1 (7.0)
 Median (IQR) 28.7 (8.1) 27.8 (7.9)
Active eczema  diagnosisa
 n (% non‑missing) 200 (100.0) 200 (100.0) 0.3347
 Yes 7 (3.5) 11 (5.5)
Active rhinitis  diagnosisa
 n (% non‑missing) 200 (100.0) 200 (100.0) 0.1056
 Yes 55 (27.5) 70 (35.0)
Eczema diagnosis
 n (% non‑missing) 200 (100.0) 200 (100.0) 0.1284
 Yes 54 (27.0) 68 (34.0)
Rhinitis diagnosis
 n (% non‑missing) 200 (100.0) 200 (100.0) 0.0858
 Yes 77 (38.5) 94 (47.0)
IHD diagnosis
 n (% non‑missing) 200 (100.0) 200 (100.0) 1.0000
 Yes 9 (4.5) 9 (4.5)
Heart failure diagnosis
 n (% non‑missing) 200 (100.0) 200 (100.0) 0.3167
 Yes 0 (0.0) 1 (0.5)
Hypertension diagnosis
 n (% non‑missing) 200 (100.0) 200 (100.0) 0.0592
 Yes 55 (27.5) 39 (19.5)
Diabetes diagnosis
 n (% non‑missing) 200 (100.0) 200 (100.0) 0.8630
 Yes 19 (9.5) 18 (9.0)
GERD active diagnosis
 n (% non‑missing) 200 (100.0) 200 (100.0) 0.0630
 Yes 35 (17.5) 22 (11.0)
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FeNO reading or a high blood eosinophil count, the exac-
erbation RR was less pronounced and non-significant 
compared with the reference group. In categorisation 2, 
patients in the high FeNO (> 35 ppb) and high eosinophil 
count (≥ 0.300 × 109 cells/L) cohort were almost twice 
as likely to have severe exacerbations in the year prior to 
the FeNO reading compared with the reference group, 
whereas the high FeNO and non-high blood eosinophil 
count cohort and non-high FeNO and high blood eosin-
ophil count cohort displayed a trend towards increased 
exacerbations relative to the reference group, that did 
not reach statistical significance. Therefore, the combina-
tion of blood eosinophil count and FeNO may be an even 
stronger marker of exacerbation risk compared with the 
individual biomarkers. Moreover, the use of the ATS cri-
teria for high FeNO (≥ 50 ppb) resulted in a greater esti-
mated exacerbation rate, indicating that a greater FeNO 
reading (≥ 50 ppb vs. ≥ 35 ppb) in the presence of a raised 
blood eosinophil count was associated with an even 
greater exacerbation rate. Notably, the exacerbation risk 
seemed to be independent of traditionally used prognos-
tic variables such as predicted peak flow and short-act-
ing β2-agonist use, which were not significantly different 
between cohorts.
The cutoffs used in the study to define high FeNO 
concentration and high blood eosinophil count warrant 
further consideration. The cutoff chosen for high blood 
eosinophil count (≥ 0.300 × 109 cells/L) was well within 
the range of peripheral blood eosinophils (usually rang-
ing between 0.200 × 109 cells/L and 0.300 × 109 cells/L) 
that most accurately predicts sputum eosinophil count 
in patients with severe asthma [36]. For FeNO classi-
fication, the ATS criteria for adults is commonly used, 
wherein the high FeNO cutoff has been set at > 50 ppb 
and low FeNO at < 25  ppb [19, 23, 37]. As cutoff con-
centrations for high, medium, and low FeNO may be 
confusing for clinicians with relatively little experi-
ence of FeNO as a biomarker, we tested a simplified 
FeNO cutoff criteria (high FeNO, ≥ 35  ppb; non-high 
FeNO, < 35 ppb) for ease of use in primary care settings. 
All values in table are n (%) unless otherwise specified. High FeNO defined as ≥ 50 ppb; non-high FeNO < 25 ppb; high blood eosinophil count defined as ≥ 0.300 × 109 
cells/L; non-high blood eosinophil count < 0.300 × 109 cells/L
ATS American Thoracic Society, BMI body mass index, FeNO fractional exhaled nitric oxide, GERD gastroesophageal reflux disease, ICS inhaled corticosteroid, IHD 
ischaemic heart disease, IQR interquartile range, LABA long-acting β2-agonist, ppb parts per billion, SABA short-acting β2-agonist, SD standard deviation
a Active denotes diagnosed in the year before FeNO reading or treated in the year before FeNO reading
b Medication Possession Ratio was calculated by dividing the total of 1 day’s supply by the total number of days evaluated, multiplied by 100%. The evaluation period 
for all patients was 365 days in the study year
Table 2 (continued)
Characteristics Non-high FeNO and non-high blood 
eosinophils (n = 200)




 n (% non‑missing) 105 (52.5) 110 (55.0) 0.7422
 Mean (SD) 516.0 (73.2) 519.4 (75.8)
 Median (IQR) 485.8 (134.7) 487.6 (137.8)
ICS/LABA prescriptions per patient
 n (% non‑missing) 200 (100.0) 200 (100.0) 0.4736
 Mean (SD) 4.1 (4.0) 4.1 (3.7)
 Median (IQR) 3.0 (5.0) 3.5 (5.0)
Mono ICS prescriptions per patient
 n (% non‑missing) 200 (100.0) 200 (100.0) 0.0112
 Mean (SD) 1.4 (2.7) 0.6 (1.6)
 Median (IQR) 0.0 (1.0) 0.0 (0.0)
Mean daily SABA dosage (µg)
 n (% non‑missing) 200 (100.0) 200 (100.0) 0.2808
 < 100 67 (33.5) 83 (41.5)
 100–200 58 (29.0) 47 (23.5)
 201–400 45 (22.5) 47 (23.5)
 > 400 30 (15.0) 23 (11.5)
ICS  adherenceb
 n (% non‑missing) 200 (100.0) 200 (100.0) 0.1931
 Mean (SD) 72.2 (72.7) 63.3 (53.3)
 Median (IQR) 61.7 (64.4) 52.0 (61.7)
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Table 3 Categorisation 2: non-high FeNO and non-high blood eosinophils vs. non-high FeNO and high blood eosinophils
Characteristics Non-high FeNO and non-high blood 
eosinophils (n = 186)
Non-high FeNO and high blood 
eosinophils (n = 186)
p-value
Sex
 n (% non‑missing) 186 (100.0) 186 (100.0) 1.0000
 Male 77 (41.4) 77 (41.4)
Age
 n (% non‑missing) 186 (100.0) 186 (100.0) 0.9834
 Mean (SD) 51.9 (13.1) 51.8 (13.7)
 Median (IQR) 55.0 (20.0) 53.5 (20.0)
Age group
 n (% non‑missing) 186 (100.0) 186 (100.0) 0.1919
 Under 35 22 (11.8) 24 (12.9)
 35–65 141 (75.8) 127 (68.3)
 44–80 23 (12.4) 35 (18.8)
Smoking status
 n (% non‑missing) 186 (100.0) 186 (100.0) 1.0000
 Non‑smoker 67 (36.0) 67 (36.0)
 Ex‑smoker 22 (11.8) 22 (11.8)
 Current smoker 67 (36.0) 67 (36.0)
BMI
 n (% non‑missing) 184 (98.4) 184 (98.4) 0.0492
 Mean (SD) 30.1 (6.3) 29.0 (6.7)
FeNO
 n (% non‑missing) 186 (100.0) 186 (100.0) <0.0001
 Mean (SD) 16.5 (7.8) 28.9 (23.8)
 Median (IQR) 16.0 (12.0) 23.0 (22.0)
Blood eosinophil count
 n (% non‑missing) 186 (100.0) 184 (98.9) <0.0001
 Mean (SD) 0.2 (0.1) 0.4 (0.2)
 Median (IQR) 0.2 (0.1) 0.4 (0.2)
Active eczema  diagnosisa
 n (% non‑missing) 186 (100.0) 186 (100.0) 0.1876
 Yes 5 (2.7) 10 (5.4)
Active rhinitis  diagnosisa
 n (% non‑missing) 186 (100.0) 186 (100.0) 0.0720
 Yes 49 (26.3) 65 (34.9)
Eczema diagnosis
 n (% non‑missing) 186 (100.0) 186 (100.0) 0.2273
 Yes 57 (30.6) 68 (36.6)
Rhinitis diagnosis
 n (% non‑missing) 186 (100.0) 186 (100.0) 0.0272
 Yes 67 (36.0) 88 (47.3)
IHD diagnosis
 n (% non‑missing) 186 (100.0) 186 (100.0) 0.4564
 Yes 7 (3.8) 10 (5.4)
Heart failure diagnosis
 n (% non‑missing) 186 (100.0) 186 (100.0) 0.3167
 Yes 0 (0.0) 1 (0.5)
Hypertension diagnosis
 n (% non‑missing) 186 (100.0) 186 (100.0) 0.3212
 Yes 46 (24.7) 38 (20.4)
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The high FeNO cutoff of ≥ 35  ppb has also been vali-
dated in several studies, in turn, identifying patients 
with uncontrolled asthma and a more severe asthma 
phenotype [31, 32]. These results suggest that a lower 
high FeNO cutoff of ≥ 35 ppb instead of ≥ 50 ppb (ATS 
criteria), on a background of raised blood eosinophil 
count, may still be relevant to predict those patients 
at significant risk of severe exacerbations. This implies 
that asthma patients with comparatively lower raised 
FeNO concentrations and elevated blood eosinophil 
count may require further treatment, suggesting that 
the risk of severe exacerbations may potentially be over 
and above that provided by a traditional severity-based 
classification.
Few studies have evaluated the predictive value of the 
combination of blood eosinophil count and FeNO con-
centration in asthma. However, available studies have 
demonstrated that combining FeNO and blood eosino-
phil count has an additive effect in predicting wheeze, 
frequent exacerbations, impaired lung function, and 
bronchial hyper-responsiveness [23, 38]. The National 
Institute for Health and Care Excellence [39] and the 
British Thoracic Society recommend FeNO measure-
ment to guide diagnosis and treatment of eosinophilic 
asthma [40]. Use of FeNO as a diagnostic tool is increas-
ing. In UK primary care practices, FeNO monitoring is 
also being used to guide decisions on ICS usage or step-
up therapy [37]. In addition, the 2019 Global Initiative 
All values in the table are n (%) unless otherwise specified. High FeNO defined as ≥ 35 ppb; non-high FeNO < 35 ppb; high blood eosinophil count defined 
as ≥ 0.300 × 109 cells/L; non-high blood eosinophil count < 0.300 × 109 cells/L
BMI body mass index, FeNO fractional exhaled nitric oxide, GERD gastroesophageal reflux disease, ICS inhaled corticosteroid, IHD ischaemic heart disease, IQR 
interquartile range, LABA long-acting β2-agonist, ppb parts per billion, SABA short-acting β2-agonist, SD standard deviation
a Active denotes diagnosed in the year before FeNO reading or treated in the year before FeNO reading
b Medication Possession Ratio was calculated by dividing the total of 1 day’s supply by the total number of days evaluated, multiplied by 100%. The evaluation period 
for all patients was 365 days in the study year
Table 3 (continued)
Characteristics Non-high FeNO and non-high blood 
eosinophils (n = 186)
Non-high FeNO and high blood 
eosinophils (n = 186)
p-value
Diabetes diagnosis
 n (% non‑missing) 186 (100.0) 186 (100.0) 0.5736
 Yes 14 (7.5) 17 (9.1)
GERD active diagnosis
 N (% non‑missing) 186 (100.0) 186 (100.0) 0.4352
 Yes 26 (14.0) 21 (11.3)
Predicted peak flow
 n (% non‑missing) 98 (52.7) 101 (54.3) 0.8525
 Mean (SD) 515.7 (75.3) 517.3 (76.2)
ICS/LABA prescriptions per patient
 n (% non‑missing) 186 (100.0) 186 (100.0) 0.0404
 Mean (SD) 3.8 (3.9) 4.4 (3.8)
 Median (IQR) 3.0 (6.0) 4.0 (5.0)
Mono ICS prescriptions per patient
 n (% non‑missing) 186 (100.0) 186 (100.0) 0.0362
 Mean (SD) 1.3 (2.5) 0.7 (1.6)
 Median (IQR) 0.0 (1.0) 0.0 (1.0)
Mean daily SABA dosage (µg)
 n (% non‑missing) 186 (100.0) 186 (100.0) 0.2585
 <100 63 (33.9) 71 (38.2)
 100–200 57 (30.6) 48 (25.8)
 201–400 35 (18.8) 45 (24.2)
 >400 31 (16.7) 22 (11.8)
ICS  adherenceb
 n (% non‑missing) 186 (100.0) 186 (100.0) 0.8806
 Mean (SD) 69.2 (55.2) 66.2 (53.3)
 Median (IQR) 54.8 (71.2) 56.1 (57.5)
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Table 4 Categorisation 2: non-high FeNO and non-high blood eosinophils vs. high FeNO and non-high blood eosinophils
Characteristics Non-high FeNO and non-high blood 
eosinophils (n = 98)
High FeNO and non-high blood 
eosinophils (n = 98)
p-value
Sex
 n (% non‑missing) 98 (100.0) 98 (100.0) 1.0000
 Male 41 (41.8) 41 (41.8)
Age
 n (% non‑missing) 98 (100.0) 98 (100.0) 1.0000
 Mean (SD) 48.8 (15.3) 48.6 (15.6)
 Median (IQR) 53.0 (27.0) 53.0 (27.0)
Age group
 n (% non‑missing) 98 (100.0) 98 (100.0) 0.3072
 Under 35 23 (23.5) 24 (24.5)
 35–65 65 (66.3) 57 (58.2)
 66–80 10 (10.2) 17 (17.3)
Smoking status
 n (% non‑missing) 98 (100.0) 98 (100.0) 1.0000
 Non‑smoker 53 (54.1) 53 (54.1)
 Ex‑smoker 8 (8.2) 8 (8.2)
 Current smoker 23 (23.5) 23 (23.5)
BMI
 n (% non‑missing) 96 (98.0) 94 (95.9) 0.0063
 Mean (SD) 29.3 (6.2) 26.9 (5.8)
 Median (IQR) 27.9 (8.6) 25.7 (7.6)
FeNO
 n (% non‑missing) 98 (100.0) 98 (100.0) < 0.0001
 Mean (SD) 17.7 (7.9) 60.0 (31.8)
 Median (IQR) 17.0 (10.0) 50.0 (25.0)
Blood eosinophil count
 n (% non‑missing) 98 (100.0) 97 (99.0) < 0.0001
 Mean (SD) 0.2 (0.1) 0.3 (0.3)
 Median (IQR) 0.2 (0.1) 0.3 (0.3)
Active eczema  diagnosisa
 n (% non‑missing) 98 (100.0) 98 (100.0) 1.0000
 Yes 4 (4.1) 4 (4.1)
Active rhinitis  diagnosisa
 n (% non‑missing) 98 (100.0) 98 (100.0) 0.7492
 Yes 26 (26.5) 28 (28.6)
Eczema diagnosis
 n (% non‑missing) 98 (100.0) 98 (100.0) 0.8763
 Yes 29 (29.6) 30 (30.6)
Rhinitis diagnosis
 n (% non‑missing) 98 (100.0) 98 (100.0) 0.4546
 Yes 32 (32.7) 37 (37.8)
IHD diagnosis
 n (% non‑missing) 98 (100.0) 98 (100.0) 0.7003
 Yes 4 (4.1) 3 (3.1)
Heart failure diagnosis
 n (% non‑missing) 98 (100.0) 98 (100.0)
 Yes 0 (0.0) 0 (0.0)
Hypertension diagnosis
 n (% non‑missing) 98 (100.0) 98 (100.0) 0.0967
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for Asthma strategy report [14] recommends the use 
of FeNO and/or blood eosinophil counts to determine 
asthma phenotype and for biomarker-guided selection 
of biologics. Thus, composite, non-invasive biomarkers, 
such as FeNO and easily obtainable blood eosinophil 
count, may provide insight into a patient’s risk of exac-
erbations as well as guide asthma treatment.
Other well-characterised risk factors for asthma exac-
erbations include prior exacerbations, OCS use, and 
underlying lung function impairment [41, 42]. The com-
bination of these standard medical history/lung function-
based assessments and objective biomarkers, such as 
FeNO and blood eosinophil count, may improve the pre-
diction of asthma exacerbations. Furthermore, within the 
limits of the data, our results indicate that the prognostic 
value of both FeNO and blood eosinophil count as com-
plementary biomarkers appears to be greater than that 
provided by these traditional clinical assessments [41, 
42].
This study has several limitations. The power analysis 
performed at the protocol stage demonstrated that more 
patients were required for sufficient power to demonstrate 
a difference between four groups than were available. 
Secondly, the OPCRD data set comprised information 
All values in the table are n (%) unless otherwise specified. High FeNO defined as ≥ 35 ppb; non-high FeNO < 35 ppb; high blood eosinophil count defined 
as ≥ 0.300 × 109 cells/L; non-high blood eosinophil count < 0.300 × 109 cells/L
BMI body mass index, FeNO fractional exhaled nitric oxide, GERD gastroesophageal reflux disease, ICS inhaled corticosteroid, IHD ischaemic heart disease, IQR 
interquartile range, LABA long-acting β2-agonist, ppb parts per billion, SABA short-acting β2-agonist, SD standard deviation
a Active denotes diagnosed in the year before FeNO reading or treated in the year before FeNO reading
b Medication Possession Ratio was calculated by dividing the total of 1 day’s supply by the total number of days evaluated, multiplied by 100%. The evaluation period 
for all patients was 365 days in the study year
Table 4 (continued)
Characteristics Non-high FeNO and non-high blood 
eosinophils (n = 98)
High FeNO and non-high blood 
eosinophils (n = 98)
p-value
 Yes 29 (29.6) 19 (19.4)
Diabetes diagnosis
 n (% non‑missing) 98 (100.0) 98 (100.0) 0.5513
 Yes 7 (7.1) 5 (5.1)
GERD active diagnosis
 n (% non‑missing) 98 (100.0) 98 (100.0) 0.6018
 Yes 9 (9.2) 7 (7.1)
Predicted peak flow
 n (% non‑missing) 55 (56.1) 71 (72.4) 0.6615
 Mean (SD) 520.7 (67.4) 515.9 (68.6)
 Median (IQR) 490.8 (137.4) 493.7 (125.0)
ICS/LABA prescriptions per patient
 n (% non‑missing) 98 (100.0) 98 (100.0) 0.1318
 Mean (SD) 2.6 (3.1) 3.4 (3.7)
 Median (IQR) 1.0 (4.0) 2.0 (5.0)
Mono ICS prescriptions per patient
 n (% non‑missing) 98 (100.0) 98 (100.0) 0.0295
 Mean (SD) 1.6 (2.8) 0.9 (1.9)
 Median (IQR) 0.0 (2.0) 0.0 (1.0)
Mean daily SABA dosage (µg)
 n (% non‑missing) 98 (100.0) 98 (100.0) 0.3731
 < 100 31 (31.6) 40 (40.8)
 100–200 32 (32.7) 22 (22.4)
 201–400 20 (20.4) 22 (22.4)
 > 400 15 (15.3) 14 (14.3)
ICS  adherenceb
 n (% non‑missing) 98 (100.0) 98 (100.0) 0.4778
 Mean (SD) 58.1 (43.5) 65.7 (67.6)
 Median (IQR) 49.3 (57.5) 49.3 (54.8)
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Table 5 Categorisation 2: non-high FeNO and non-high blood eosinophils vs. high FeNO and high blood eosinophils
Characteristics Non-high FeNO and non-high blood 
eosinophils (n = 53)




 n (% non‑missing) 53 (100.0) 53 (100.0) 1.0000
 Male 48.4 (16.7) 48.2 (16.9)
Age
 n (% non‑missing) 53.0 (100.0) 53.0 (100.0) 0.9647
 Mean (SD) 48.4 (16.7) 48.2 (16.9)
 Median (IQR) 53.0 (32.0) 53.0 (31.0)
Age group
 n (% non‑missing) 53 (100.0) 53 (100.0) 0.8655
 Under 35 14 (26.4) 14 (26.4)
 35–65 31 (58.5) 29 (54.7)
 66–80 8 (15.1) 10 (18.9)
Smoking status
 n (% non‑missing) 46 (86.8) 46 (86.8) 1.0000
 Non‑smoker 31 (58.5) 31 (58.5)
 Ex‑smoker 4 (7.5) 4 (7.5)
 Current smoker 11 (20.8) 11 (20.8)
BMI
 n (% non‑missing) 52 (98.1) 51 (96.2) 0.0386
 Mean (SD) 29.0 (5.9) 26.8 (5.6)
 Median (IQR) 28.4 (8.3) 25.6 (7.1)
FeNO
 n (% non‑missing) 53 (100.0) 53 (100.0) < 0.0001
 Mean (SD) 18.6 (7.7) 57.8 (26.4)
 Median (IQR) 20.0 (10.0) 49.0 (28.0)
Blood eosinophil count
 n (% non‑missing) 53 (100.0) 52 (98.1) < 0.0001
 Mean (SD) 0.1 (0.1) 0.5 (0.3)
 Median (IQR) 0.1 (0.1) 0.5 (0.2)
Active eczema  diagnosisa
 n (% non‑missing) 53 (100.0) 53 (100.0) 1.0000
 Yes 2 (3.8) 2 (3.8)
Active rhinitis  diagnosisa
 n (% non‑missing) 53 (100.0) 53 (100.0) 0.4052
 Yes 15 (28.3) 19 (35.8)
Eczema diagnosis
 n (% non‑missing) 53 (100.0) 53 (100.0) 0.5355
 Yes 16 (30.2) 19 (35.8)
Rhinitis diagnosis
 n (% non‑missing) 53 (100.0) 53 (100.0) 0.0451
 Yes 15 (28.3) 25 (47.2)
IHD diagnosis
 n (% non‑missing) 53 (100.0) 53 (100.0) 0.5581
 Yes 1 (1.9) 2 (3.8)
Heart failure diagnosis
 n (% non‑missing) 53 (100.0) 53 (100.0)
 Yes 0 (0.0) 0 (0.0)
Hypertension diagnosis
 n (% non‑missing) 53 (100.0) 53 (100.0) 0.0990
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collected for clinical and routine use rather than specifi-
cally for research purposes. Although extensive quality 
control and validity checks were conducted at the practice 
level, the validity and completeness of individual patient 
records can be limited. Since blood eosinophil measure-
ments and FeNO readings are not collected routinely, 
patients with asthma who had both blood eosinophil 
counts and FeNO measured may not have been repre-
sentative of the overall asthma population. In addition, the 
time from when the blood eosinophil count reading was 
taken to the index date varied considerably. Although high 
blood eosinophil counts have been observed to be a stable 
phenotype, at least during a 1-year period [11], further 
studies are required to investigate the potential long-term 
stability of blood eosinophil counts. As with all observa-
tional studies, confounding variables, arising from system-
atic differences between the patients being compared, may 
have complicated interpretation of these results. In this 
study, confounding was minimised by fitting multivariate 
models that adjusted patient characteristics that may have 
varied between patient groups. However, despite these 
measures, confounding by unmeasured variables may have 
been present. Finally, adherence to ICS was not a prereq-
uisite to enter the study, and as a result adherence was not 
All values in the table are n (%) unless otherwise specified. High FeNO defined as ≥ 35 ppb; non-high FeNO < 35 ppb; high blood eosinophil count defined 
as ≥ 0.300 × 109 cells/L; non-high blood eosinophil count < 0.300 × 109 cells/L
BMI body mass index, FeNO fractional exhaled nitric oxide, GERD gastroesophageal reflux disease, ICS inhaled corticosteroid, IHD ischaemic heart disease, IQR 
interquartile range, LABA long-acting β2-agonist, ppb parts per billion, SABA short-acting β2-agonist, SD standard deviation
a Active denotes diagnosed in the year before FeNO reading or treated in the year before FeNO reading
b Medication Possession Ratio was calculated by dividing the total of 1 day’s supply by the total number of days evaluated, multiplied by 100%. The evaluation period 
for all patients was 365 days in the study year
Table 5 (continued)
Characteristics Non-high FeNO and non-high blood 
eosinophils (n = 53)
High FeNO and high blood eosinophils 
(n = 53)
p-value
 Yes 15 (28.3) 8 (15.1)
Diabetes diagnosis
 n (% non‑missing) 53 (100.0) 53 (100.0) 1.0000
 Yes 3 (5.7) 3 (5.7)
GERD active diagnosis
 n (% non‑missing) 53 (100.0) 53 (100.0) 0.5063
 Yes 6 (11.3) 4 (7.5)
Predicted peak flow
 n (% non‑missing) 35 (66.0) 39 (73.6) 0.8838
 Mean (SD) 513.0 (66.7) 510.3 (69.9)
 Median (IQR) 487.5 (122.0) 481.2 (128.0)
ICS/LABA prescriptions per patient
 n (% non‑missing) 53 (100.0) 53 (100.0) 0.2204
 Mean (SD) 3.3 (3.9) 4.0 (4.0)
 Median (IQR) 2.0 (5.0) 3.0 (5.0)
Mono ICS prescriptions per patient
 n (% non‑missing) 53 (100.0) 53 (100.0) 0.1944
 Mean (SD) 1.3 (2.3) 0.8 (1.7)
 Median (IQR) 0.0 (1.0) 0.0 (1.0)
Mean daily SABA dosage (µg)
 n (% non‑missing) 53 (100.0) 53 (100.0) 0.6923
 < 100 15 (28.3) 16 (30.2)
 100–200 19 (35.8) 14 (26.4)
 201–400 10 (18.9) 14 (26.4)
 > 400 9 (17.0) 9 (17.0)
ICS  adherenceb
 n (% non‑missing) 53 (100.0) 53 (100.0) 0.8149
 Mean (SD) 64.1 (45.3) 68.6 (72.5)
 Median (IQR) 54.8 (54.8) 49.3 (49.3)
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optimal. While ICS adherence between each cohort and 
reference group was not significantly different, it is likely 
that FeNO concentrations and blood eosinophil counts 
may be differentially predictive in patients receiving or not 
receiving their prescribed ICS medications.
Results of this study need to be confirmed in a prospec-
tive study in a larger patient population before high FeNO 
concentrations and high blood eosinophil counts can be 
advocated as a composite biomarker. Notably, patients 
with elevated FeNO concentration on a background of 
high blood eosinophil counts represent a potentially 
high-risk group of patients. Such severe asthma patients 
will benefit from studies conducted in larger epidemio-
logical cohorts in primary care settings, as well as in 
severe asthma cohorts, such as the International Severe 
Asthma Registry [43], a global registry of adult patients 
with severe asthma, and the CHRONICLE study [44], an 
ongoing non-interventional, prospective cohort study of 
adults with severe asthma treated by specialists in the 
United States. Overall, findings from this study, based on 
real-life data obtained from a validated database, warrant 
further investigation into the role of FeNO and blood 
eosinophils as biomarkers in the treatment and manage-
ment of asthma.
Conclusions
The combination of raised FeNO concentrations and 
raised blood eosinophil counts was associated with a 
greater exacerbation rate compared with neither bio-
marker raised in the year preceding the FeNO reading. 
FeNO concentration and blood eosinophil count are 
simple measurements that could, together, improve the 
identification of patients with asthma in primary and sec-
ondary care at risk of exacerbations, and thus, guide addi-
tional considerations in the treatment of their asthma.
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